7 research outputs found

    Tropospheric Ozone Assessment Report : database and metrics data of global surface ozone observations

    No full text
    202209 bckwVersion of RecordRGCOthersARIES; CE-ORACLEO3; Department of Earth Sciences RAS; Helmholtz; IISER Mohali Atmospheric Chemistry Facility; ISRO-ATCTM; ISRO-GBP; MARACA; National Centre for Atmospheric Science Atmospheric Measurement Facility; National Science Foundation; U.S. Department of Energy; Directorate for Geosciences; National Oceanic and Atmospheric Administration; New York State Energy Research and Development Authority; Aneurysm and AVM Foundation; Natural Environment Research Council; National Centre for Atmospheric Science; Department of Science and Technology, Ministry of Science and Technology, India; Indian Space Research Organisation; Fundação de Amparo à Pesquisa do Estado de São Paulo; National Natural Science Foundation of China; Comisión Nacional de Investigación Científica y Tecnológica; Fondo Nacional de Desarrollo Científico y Tecnológico; Forschungszentrum Jülich; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Hong Kong Polytechnic University; Ministry of Human Resource Development; Centre National de la Recherche Scientifique; Institut Polaire Français Paul Emile Victor; World Meteorological Organization; Commissariat à l'Énergie Atomique et aux Énergies Alternatives; Russian Science Foundation; MiljødirektoratetPublishe

    Liraglutide and Renal Outcomes in Type 2 Diabetes.

    No full text
    BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a composite of new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease. The risk of renal outcomes was determined with the use of time-to-event analyses with an intention-to-treat approach. Changes in the estimated glomerular filtration rate and albuminuria were also analyzed. RESULTS: A total of 9340 patients underwent randomization, and the median follow-up of the patients was 3.84 years. The renal outcome occurred in fewer participants in the liraglutide group than in the placebo group (268 of 4668 patients vs. 337 of 4672; hazard ratio, 0.78; 95% confidence interval [CI], 0.67 to 0.92; P=0.003). This result was driven primarily by the new onset of persistent macroalbuminuria, which occurred in fewer participants in the liraglutide group than in the placebo group (161 vs. 215 patients; hazard ratio, 0.74; 95% CI, 0.60 to 0.91; P=0.004). The rates of renal adverse events were similar in the liraglutide group and the placebo group (15.1 events and 16.5 events per 1000 patient-years), including the rate of acute kidney injury (7.1 and 6.2 events per 1000 patient-years, respectively). CONCLUSIONS: This prespecified secondary analysis shows that, when added to usual care, liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048 .)

    Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

    No full text
    corecore